WPD Pharmaceuticals Inc. announced that first patient enrolled in the Phase 1B/2 clinical trial of Annamycin in the treatment of soft tissue sarcoma (STS) lung metastases, has received the first dose of Annamycin. The start of clinical trial is a consequence of the project granted by Agencja Bada Medycznych (The Medical Research Agency), that was communicated by WPD in a news release dated February 9, 2021. Agencja Bada Medycznych (The Medical Research Agency) is a Polish state agency responsible for development of scientific research in the field of medical and health sciences, awarded a grant equivalent to USD 1.5 million to the Maria Sklodowska-Curie National Research Institute to fund a Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 CAD | -50.00% | -50.00% | -88.89% |
1st Jan change | Capi. | |
---|---|---|
-88.89% | 422K | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- WBIO Stock
- News WPD Pharmaceuticals Inc.
- WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin